Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 347 across all filing types
Latest filing 2023-01-24 Investor Presentation
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Investor Presentation Classification · 95% confidence The document is titled "MaaT Pharma Provides Corporate Update and Highlights Key Expected Milestones in 2023" and details progress across several clinical programs (MaaT013, MaaT033), regulatory discussions (FDA, EMA), and pipeline extensions (ALS research). It provides detailed operational and scientific updates, including expected timelines for data readouts (e.g., H1 2023, H2 2024, H1 2026) and adjustments to trial protocols (Phase 2b expansion). This content structure—a comprehensive review of the past year's achievements and a forward-looking roadmap with specific clinical and regulatory milestones—is characteristic of an Investor Presentation (IP) or a detailed Management Discussion and Analysis (MDA). Given the focus on scientific progress, clinical trial specifics, and future strategic outlook presented in a narrative/slide-like format (though transcribed here), 'Investor Presentation' (IP) is the most fitting category, as it serves to inform investors about the company's current status and future value drivers, which is more detailed than a simple Earnings Release (ER) or a general Regulatory Filing (RNS). It is not a formal financial report (10-K or IR).
2023-01-24 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 95% confidence The document is a press release from MaaT Pharma dated January 24, 2023, titled "MaaT Pharma fait le point sur son état d'avancement et annonce les étapes clés attendues pour 2023" (MaaT Pharma provides an update on its progress and announces key milestones expected for 2023). The text details clinical trial progress (Phase 3, Phase 2a, Phase 1b planning), regulatory interactions (FDA, EMA), pipeline updates (MaaT013, MaaT033, MaaT03x), and expected timelines for results and milestones throughout 2023 and beyond. This content structure—a comprehensive update on business operations, clinical development, and future outlook—is characteristic of an Investor Presentation (IP) or a detailed Management Discussion and Analysis (MDA). Given the focus on scientific progress, clinical trial adjustments, and future strategic inflection points, it aligns best with an Investor Presentation (IP) which often serves to update investors on strategy and pipeline execution, although it shares characteristics with an MDA. Since it is a formal update detailing strategy and pipeline execution rather than just financial results (ER) or a formal annual report (10-K), IP is the most fitting category for this type of forward-looking, detailed operational update.
2023-01-24 French
Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
Capital/Financing Update Classification · 99% confidence The document is explicitly titled "MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux" and provides detailed figures regarding share balances and trading activity under a liquidity contract as of December 31st, 2022. This report covers a period shorter than a full year (half-year) and details financial/operational data, fitting the description of an Interim/Quarterly Report (IR). Although it is a specific type of report (liquidity contract report), among the provided codes, 'IR' (Interim / Quarterly Report) is the most appropriate classification for a comprehensive half-year financial disclosure, distinct from a brief Earnings Release (ER) or a general Audit Report (AR). It is a report itself, not an announcement of a report (RPA/RNS).
2023-01-09 English
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Transaction in Own Shares Classification · 98% confidence The document is titled "MaaT Pharma : Bilan semestriel du contrat de liquidité contracté avec la société de bourse Kepler Cheuvreux" (MaaT Pharma: Semi-annual balance sheet of the liquidity contract entered into with the brokerage firm Kepler Cheuvreux). It explicitly details the status of a liquidity contract (share buyback/liquidity provision agreement) as of December 31, 2022, comparing it to the previous balance date (June 30, 2022). This type of announcement, detailing the activity related to the company managing its own shares (often for market stabilization or liquidity provision), falls under the category of 'Transaction in Own Shares' (POS), which covers share repurchase/issuance activities. Although it is a report/balance sheet, it is not a comprehensive financial report (10-K or IR), nor is it a general announcement of a report (RPA). It is a specific regulatory disclosure related to share transactions managed under a contract.
2023-01-09 French
Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
Report Publication Announcement Classification · 99% confidence The document is titled "MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux" and provides detailed figures regarding share transactions (buy side/sell side executions, volume, cash value) on the liquidity account as of December 31st, 2022, comparing it to June 30th, 2022. This type of regular disclosure concerning market making or liquidity provision activities, often mandated by local regulators (AMF mentioned here), is a specific type of financial disclosure. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR) which focuses on P&L/Balance Sheet. It is a specific regulatory filing related to market operations. Given the options, this specialized report on liquidity management does not fit perfectly into the standard categories like 10-K, IR, or ER. It is a specific regulatory disclosure. Since it is a detailed report on a specific financial/regulatory activity, and not just an announcement of a report (RPA), the most appropriate general category for a specific, non-standard regulatory disclosure is 'Regulatory Filings' (RNS), or potentially a specialized category if one existed. However, looking closely at the definitions, none perfectly capture a 'Liquidity Contract Report'. Since it is a formal, periodic report detailing specific financial/market activities required by regulation (AMF Decision), and it is not a general earnings or interim report, it falls best under the general regulatory disclosure category, RNS, as a fallback for specific, non-core reporting documents.
2023-01-09 English
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Capital/Financing Update Classification · 99% confidence The document is titled "MaaT Pharma : Bilan semestriel du contrat de liquidité contracté avec la société de bourse Kepler Cheuvreux" (MaaT Pharma: Semi-annual balance sheet of the liquidity contract entered into with the brokerage firm Kepler Cheuvreux). It details the holdings (shares and cash) and transaction volumes (buys and sells) related to a liquidity contract as of December 31, 2022, comparing it to the previous balance on June 30, 2022. This type of report concerns the management of company shares, specifically related to market making or liquidity provision, which falls under capital structure or share activity reporting. While it relates to shares, it is not a general share issue (SHA) or a transaction in own shares (POS) in the typical sense of a buyback program announcement, but rather a report on a specific contractual arrangement. However, the content is highly specific to the management of the company's stock liquidity, which is a form of capital/financing activity or insider/related party activity. Given the options, this is a report detailing the status of a financial arrangement concerning the company's stock, which is closest to a Capital/Financing Update (CAP) or potentially a specialized regulatory filing. Since it is a formal, periodic report detailing the status of a financial arrangement (liquidity contract) mandated by regulatory practice (AMF decision mentioned), and it is not a standard financial report (10-K, IR, ER), it fits best as a specific type of regulatory/financial disclosure. The closest fit among the provided codes for a report detailing the status of a stock liquidity contract is 'CAP' (Capital/Financing Update), as liquidity contracts are financing tools. Alternatively, if it were purely a regulatory filing without a better fit, 'RNS' would apply, but 'CAP' is more descriptive of the content. Revisiting the definitions, 'CAP' is for fundraising, financing activities, or capital structure changes. A liquidity contract is a financing/market stabilization tool. 'POS' is for the company buying back or selling its own shares (repurchase/issuance), which is what the contract facilitates, but this document is the *report* on the contract's status, not the announcement of a new repurchase program. 'CAP' remains the most appropriate category for reporting on the status of a financing/stabilization mechanism. Confidence is high due to the explicit nature of the report content.
2023-01-09 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.